Adaptimmune Therapeutics plc ADAPY
As ofNov 19, 2026, 3:50 PM EST
- YTD
- +15.38%
- 1 year
- -50.82%
ADAPY free cash flow history
Free cash flow is operating cash flow minus capital expenditure outflow. It can be negative; it is not the same as earnings.
-74,092,000 USD
FY 2024 · Period ended
Coverage: stale. Values in USD; not inflation adjusted.
Reporting currency is USD by the source’s USD conversion factor of 1; the source does not name the currency.
Capital expenditure here is net of asset disposals, so free cash flow can be higher than a figure that subtracts gross purchases.
Scroll the table to see all values →
| Fiscal period | Period end | Free cash flow | YoY change | YoY % |
|---|---|---|---|---|
| FY 2024 | 2024-12-31 | -74,092,000 | 71,469,000 | Not meaningful |
| FY 2023 | 2023-12-31 | -145,561,000 | 25,704,000 | Not meaningful |
| FY 2022 | 2022-12-31 | -171,265,000 | -173,420,000 | -8047.33% |
| FY 2021 | 2021-12-31 | 2,155,000 | 58,087,000 | Not meaningful |
| FY 2020 | 2020-12-31 | -55,932,000 | 58,167,000 | Not meaningful |
| FY 2019 | 2019-12-31 | -114,099,000 | -5,801,000 | Not meaningful |
| FY 2018 | 2018-12-31 | -108,298,000 | -29,890,000 | Not meaningful |
| FY 2017 | 2017-12-31 | -78,408,000 | -18,734,000 | Not meaningful |
| FY 2016 | 2016-12-31 | -59,674,000 | Not available | Not available |
| FY 2015 | 2015-06-30 | -34,624,000 | -70,093,000 | -197.62% |
| FY 2014 | 2014-06-30 | 35,469,000 | Not available | Not available |
Percentage growth is shown only when the same fiscal period one year earlier has a positive value. Missing periods are not estimated.
Company-reported financial statements. Retrieved 2025-10-31T11:55:19.000Z. Retrieval time is not a report date.
Open full statementsUse Add to watchlist above to save this stock.
